Zhiqiang Meng

机构：Fudan University Shanghai Cancer Center · ORCID：0000-0003-3593-6098

发表论文 218 篇 · 总被引 13569 次 · h-index 54

代表论文

• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 267)
• Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 47)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study (2024 · Molecular Therapy · 被引 32)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 24)
• Oncofetal TRIM71 drives liver cancer carcinogenesis through remodeling CEBPA-mediated serine/glycine metabolism (2024 · Theranostics · 被引 20)